Adrenocortical carcinoma cost-effectiveness of therapy

Overview

Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years and surveillance intervals may be increased to 6 months for the next 5 years. Surveillance includes cross-sectional imaging of chest, abdomen, and pelvis, the use of FDG-PET for lesions of an unclear nature, laboratory evaluation for steroid hormones and evaluation of side effects in case of adjuvant mitotane therapy.

Cost-effectiveness of therapy:

Adrenocortical carcinoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Adrenocortical carcinoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
MRI
CT
Ultrasound
Other Imaging Studies
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Radiation Therapy
Primary prevention
Secondary prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Study
Case #1
Adrenocortical carcinoma cost-effectiveness of therapy On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Adrenocortical carcinoma cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Adrenocortical carcinoma cost-effectiveness of therapy
CDC on Adrenocortical carcinoma cost-effectiveness of therapy
Adrenocortical carcinoma cost-effectiveness of therapy in the news
Blogs on Adrenocortical carcinoma cost-effectiveness of therapy
Hospitals Treating Adrenocortical carcinoma
Risk calculators and risk factors for Adrenocortical carcinoma cost-effectiveness of therapy

• Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years.

• Surveillance intervals may be increased to 6 months for the next 5 years.

• Surveillance should also include:
  • Cross-sectional imaging of chest, abdomen, and pelvis
  • The use of FDG-PET for lesions of an unclear nature
  • Laboratory evaluation for steroid hormones
  • Evaluation of side effects is also important in case of adjuvant mitotane therapy